A court case between Pfizer (PFE) and generic drug manufacturers, which will determine control of the $16.5 billion-plus Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market, is less than two weeks away.
Analysts and investors alike are speculating what the result will be. While early settlement has been floated as a possibility, Pfizer will be confident in its position and could take the case all the way to a win.
But why is this case so important?
Pfizer and the ATTR-CM market
Well, the size of the prize. The Pfizer Inc. v. Dexcel Pharma Technologies Limited case relates to the therapy that treats the progressive and debilitating heart disease ATTR-CM. In 2024, the market for the treatment was valued at $6 billion-plus. This is expected to grow rapidly to $16.5 billion-plus in 2030. Pfizer understandably wants to protect their ATTR-CM treatment revenue by keeping generic manufacturers out of the market.
Generics manufacturers are challenging Pfizer over its competitors because for five years, Pfizer manufactured the only two drugs that treated ATTR-CM: Vyndaqel and Vyndamax, both made of Tafamidis.
Here is where Pfizer’s crafty tactics become relevant for investors. Ahead of Vyndaqel’s 2028 patent expiry, Pfizer pre-emptively discontinued the drug, transitioning the vast majority of ATTR-CM patients onto Vyndamax.
If Vyndaqel generics arrive in 2028, very few patients will be prescribed it. This will make those generics less commercially viable, causing the opportunity to disappear, and ensuring Vyndamax’s market share.
This is what the three generic challengers are seeking to change. They see the opportunity to enter a growing market and want a slice.
Next generation competitors, BridgeBio (BBIO) and Alnylam (ALNY), entered the ATTR-CM treatment market after generic manufacturers first filed an Abbreviated New Drug Application (ANDA) for a generic version of Vyndamax. This explains why Pfizer’s treatment is being targeted by generic manufacturers and not that of their competitors.
Pfizer’s case against generic manufacturers
The Pfizer Inc. v. Dexcel Pharma Technologies Limited lawsuit begins on the 27 April. It involves Pfizer, the plaintiff, suing three generics manufacturers to protect their patent on Vyndamax, whose patent expires in 2035.
The three generics manufacturers who are seeking to invalidate Pfizer’s patent are: Dexcel Pharma Technologies, Cipla Ltd (CIPLA), and Hikma Pharmaceuticals PLC (HIK).
In the case, Pfizer argues that Dexcel’s submission of an ANDA to the Food and Drug Administration (FDA) for a generic version of Vyndamax is an act of infringement of the patent for specific crystalline forms of the compound. Given the difficulty that the generic challengers will have in proving that Pfizer’s patent is invalid and has not been infringed, a Pfizer win is the most likely outcome.
What would this mean for the various stakeholders?
A win for Pfizer in the lawsuit is a win for Pfizer’s business
Should Pfizer win, they would maintain control of the Vyndamax patent until at least 2035, ensuring generic competition is frozen out of the ATTR-CM market for another decade.
This would protect Vyndamax’s reimbursement price, enabling the multinational to continue earning significant revenue from the market each year. It would also enable Pfizer to use its dominance to develop other products in the future.
What would losing the case mean for generic manufacturers?
A Pfizer win for the three generic manufacturers would be worst case scenario. It would leave the challengers with nothing to show for their litigation efforts, significant legal expenditure, and locked out of the market until 2035 at the earliest.
What does a Pfizer win mean for ATTR-CM competitors BridgeBio and Alnylam?
Pfizer’s current competition in the ATTR-CM market is BridgeBio and Alnylam who received FDA approval for their treatments in 2024 and 2025 respectively. BridgeBio manufactures a product called Attruby, and Alnylam another called AMVUTTRA.
If Pfizer emerges victorious, BridgeBio and Alnylam will be able to manufacture and sell their treatment until at least 2035 before generics can enter the market and disrupt the price. It will enable BridgeBio and Alnylam to erode Pfizer’s market share by competing on efficacy and real-world outcomes.
Pfizer victory is the probable outcome
With access to a $6 billion-plus market on the line, investors and analysts expect that Pfizer Inc. v. Dexcel Pharma Technologies Limited will be one of the most consequential patent cases of 2026.
And while it is true that there is a lot at stake, a Pfizer win is thought to be the most likely result, delivering positive outcomes for Pfizer and its competitors in the ATTR-CM market, and a crushing blow to generics manufacturers.
